Rigel Pharmaceuticals, Inc. (RIGL) Reports Q3 Loss of $0.25
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $42.58 --0%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q3 EPS of ($0.25), versus $0.96 reported last year. Revenue for the quarter came in at $4.35 million, versus $72.28 thousand reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rigel Pharmaceuticals (RIGL) PT Raised to $49 at Piper Sandler
- Seritage Growth Properties (SRG) Reports Q2 Loss of $0.13
- Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
